FUNDAMENTALS · Fundamentals · US Healthcare

Janux Therapeutics (JANX) Fundamentals 2026 — Revenue Analysis | SniperIQ

Janux Therapeutics (JANX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $955M, trading at

5.66 on the NASDAQ. This SniperIQ fundamentals page covers Janux Therapeutics's valuation, profitability (net margin -529.7%), revenue (
0M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$955M
Net Margin-529.7%
Revenue (FY25)
0M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Janux Therapeutics's market cap?

Janux Therapeutics (JANX) has a market capitalization of approximately $955M, trading at

5.66 on the NASDAQ. Market cap moves with the live share price.

What is Janux Therapeutics's P/E ratio?

Janux Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Janux Therapeutics?

Janux Therapeutics runs a net profit margin of -529.7%, a gross margin of -80.8%, and an operating margin of -726.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Janux Therapeutics generate?

Janux Therapeutics reported revenue of

0M for fiscal year 2025, with net income of -
14M and earnings per share (EPS) of -1.83. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Janux Therapeutics pay a dividend?

Janux Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Janux Therapeutics financially healthy?

Janux Therapeutics carries a debt-to-equity ratio of 0.02x and a current ratio of 17.01x, with a market beta of 2.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Janux Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Janux Therapeutics (JANX) the key facts are: market cap $955M, revenue

0M, 52-week range 12.12-35.34. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Janux Therapeutics's full fundamentals live

Get Janux Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Alto Neuroscience (ANRO) fundamentals · Pharming Group (PHAR) fundamentals · Sipai Health Technology (0314) fundamentals · Kura Oncology (KURA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons